Abstract
Temozolomide (TMZ) is an oral alkylating agent used during concurrent and adjuvant chemotherapy for newly diagnosed glioblastoma multiforme. Temozolomide is generally well tolerated and improves survival; however, severe adverse events have occasionally been reported. Here, we report the case of a patient who developed aplastic anemia with related complications in the setting of concurrent TMZ treatment with radiotherapy. This case illustrates that aplastic anemia is a rare side effect of TMZ that can occur relatively early in the course of concurrent chemotherapy, and underscores the importance of clinician awareness of this potentially devastating side effect.
Original language | English (US) |
---|---|
Pages (from-to) | 124-126 |
Number of pages | 3 |
Journal | Current Oncology |
Volume | 17 |
Issue number | 4 |
DOIs | |
State | Published - 2010 |
Externally published | Yes |
Keywords
- Aplastic anemia
- Glioblastoma multiforme
- Pancytopenia
- Temozolomide
ASJC Scopus subject areas
- Oncology